Vaxart (VXRT) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
6 Jan, 2026Opening remarks and agenda
Chair welcomed attendees, introduced key executives, and outlined meeting rules and agenda.
Outside counsel and independent accounting firm representatives were introduced.
Formal business included four proposals, with Q&A to follow.
Board and executive committee updates
Inspector of Election appointed and sworn in to oversee voting process.
Board and management committed to considering shareholder feedback, especially regarding the reverse stock split.
Shareholder proposals
Director Election Proposal: Election of six directors to serve until the next annual meeting.
Reverse Stock Split Proposal: Amendment to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50.
Accountant Ratification Proposal: Ratification of WithumSmith+Brown, PC as independent accounting firm for 2025.
Say-on-Pay Proposal: Non-binding advisory vote on executive compensation.
Latest events from Vaxart
- Oral vaccine platform advances with global partnerships, cost savings, and key data expected in 2026.VXRT
Fireside chat13 Mar 2026 - 2025 revenue hit $237.3M, with profitability and pivotal vaccine trials advancing.VXRT
Q4 202512 Mar 2026 - Oral pill vaccine platform advances with strong clinical progress, partnerships, and 2026 milestones.VXRT
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Oral pill vaccine platform advances with pivotal trials and strong financial runway into 2027.VXRT
Corporate presentation25 Feb 2026 - Secured $453M BARDA contract, strong liquidity, and advanced COVID-19 and norovirus programs.VXRT
Q2 20242 Feb 2026 - Q3 revenue doubled, net loss narrowed, and vaccine programs advanced with BARDA support.VXRT
Q3 202414 Jan 2026 - Oral pill vaccines show promise for broad, convenient immunization, with pivotal trial results due in 2026.VXRT
Global BioInnovation Forum 202613 Jan 2026 - Oral pill vaccine platform shows broad efficacy and strong pipeline, with major milestones ahead.VXRT
Corporate Presentation9 Jan 2026 - Revenue rose to $28.7M as net loss narrowed and vaccine programs advanced amid restructuring.VXRT
Q4 202426 Dec 2025